Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-22T18:23:47.441Z Has data issue: false hasContentIssue false
  • English
  • Français

The Paradox of Quetiapine in Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Constantin Tranulis ,
Stéphane Potvin ,
Martin Gourgue ,
Gérard Leblanc ,
Adham Mancini-Marïe  and
Emmanuel Stip
Get access Rights & Permissions [Opens in a new window]

Abstract

Schizophrenia and obsessive-compulsive disorder (OCD) have historical, clinical, and epidemiological links. The clinical use of atypical neuroleptics (ie, dual serotonin-dopamine antagonists) to treat both conditions sheds a new light on them. We report the first two cases of obsessive-compulsive symptoms (OCS) induced by quetiapine in schizophrenia patients. A case of successful augmentation by quetiapine in refractory OCD is also presented. A review of the literature on OCS induced by atypical neuroleptics follows. This paradoxically induced OCD symptomology in schizophrenia patients administered atypical neuroleptics is discussed from new pathophysiological and clinical perspectives. The discussion emphasizes the prognostic implications of OCS in schizophrenia and available therapies for this comorbidity.

Type
Case Report
Information
CNS Spectrums , Volume 10 , Issue 5 , May 2005 , pp. 356 - 361
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Doubremelle, C, Millet, B, Olie, JP. Schizophrenic with obsessive-compulsive disorder or symptoms [French]. Encephale. 2000;26:81–88.Google Scholar
2.Fenton, WS, McGlashan, TH. The pronostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986;143:437–441.Google Scholar
3.Rosen, I. The clinical significance of obsessions in schizophrenia. J Ment Sci. 1957;103:778–785.Google Scholar
4.Berman, I, Kalinowski, A, Berman, SM, et al. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry. 1995;36:6–10.Google Scholar
5.Ozdemir, O, Tuckel, R, Tuksoy, N, et al. Clinical characteristics in obsessive-compulsive disorder with schizophrenia. Compr Psychiatry. 2003;44:311–316.Google Scholar
6.McDougle, CJ, Goodman, WK, Leckman, JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302–308.CrossRefGoogle ScholarPubMed
7.Denys, D, Van Megen, H, Westenberg, H. Quetiapine addition to serotonin reputake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002;63:700–703.Google Scholar
8.Mohr, N, Vythilingum, B, Emsley, RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002;17:37–40.Google Scholar
9.Atmaca, M, Kuloglu, M, Tezcan, E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115–119.Google Scholar
10.Sevincok, L, Topuz, A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:448–450.Google Scholar
11.Howland, RH. Chlorpromazine and obsessive-compulsive symptoms. Am J Psychiatry. 1996;153:1503.Google Scholar
12.Lykouras, L, Alevizos, B, Michalopoulou, P, et al. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:333–346.Google Scholar
13.Baker, RW, Ames, D, Umbricht, DS, et al. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull. 1996;32:89–93.Google Scholar
14.Reznik, I, Yavin, I, Stryjer, R, et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry. 2004;37:52–56.Google Scholar
15.Ghaemi, SN, Zarate, CA Jr, Popli, AP, et al. Is there a relationship between clozapine and obsessive-compulsive disorder?: a retrospective chart review. Compr Psychiatry. 1995;36:267–270.Google Scholar
16.Khullar, A, Chue, P, Tibbo, P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001;26:55–59.Google ScholarPubMed
17.de Haan, L, Beuk, N, Hoogenboom, B, et al. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002;63:104–107.CrossRefGoogle ScholarPubMed
18.de Haan, L, Linszen, DH, Gorsira, R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999;60:364–365.Google Scholar
19.Rabe-Jaboska, J. Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia [Polish]. Psychiatria Polska. 2001;35:47–57.Google Scholar
20.Alexander, GE, Crutcher, MD. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci. 1990;13:266–271.Google Scholar
21.Steingard, S, Chengappa, KN, Baker, RW, et al. Clozapine, obsessive symptoms, and serotonergic mechanisms. Am J Psychiatry. 1993;150:1435.Google Scholar
22.Levkovitch, Y, Kronnenberg, Y, Gaoni, B. Can clozapine trigger OCD? J Am Acad Child Adolesc Psychiatry. 1995;34:263.Google Scholar
23.Mahendran, R. Obsessional symptoms associated with risperidone treatment. Aust N Z J Psychiatry. 1998;32:299–301.Google Scholar
24.Dryden-Edwards, RC, Reiss, AL. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol. 1996;6:139–145.Google Scholar
25.Alzaid, K, Jones, BD. A case report of risperidone-induced obsessive-compulsive symptoms. J Clin Psychopharmacol. 1997;17:58–59.Google Scholar
26.Chong, SA, Tan, CH, Lee, HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry. 1996;41:315–316.Google Scholar
27.Alevizos, B, Lykouras, L, Zervas, IM, et al. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol. 2002;22:461–467.Google Scholar
28.Dodt, JE, Byerly, MJ, Cuadros, C, et al. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry. 1997;154:582.Google Scholar
29.Kopala, L, Honer, WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1994;151:1714–1715.Google ScholarPubMed
30.Lykouras, L, Zervas, IM, Gournellis, R, et al. Olanzapine and obsessive-compulsive symptoms. Eur Neuropsychopharmacol. 2000;10:385–387.Google Scholar
31.Morrison, D, Clark, D, Goldfarb, E, et al. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998;155:855.Google ScholarPubMed
32.Mahendran, R. Obsessive-compulsive symptoms with risperidone. J Clin Psychiatry. 1999;60:261–263.Google Scholar
33.Baxter, LR, Clark, EC, Iqbal, M, et al. Cortico-subcortical systems in the mediation of obsessive-compulsive disorder. In: Lichter, DG, Cummings, JL, eds. Fronto-sucortical Circuits in Psychiatric and Neurological Disorders. New York, NY: Guilford Press; 2001;207–230.Google Scholar
34.Cavallaro, R, Cavedini, P, Mistretta, P, et al. Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. Biol Psychiatry. 2003;54:437–443.Google Scholar
35.Kaplan, A, Hollander, E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv. 2003;54:1111–1118.Google Scholar
36.Kapur, S, Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466–476.Google Scholar
37.Mottard, JP, De la Sablonniere, JR. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry. 1999;156:799–800.Google Scholar
38.Marek, GJ, Carpenter, LL, McDougle, CJ, et al. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28:402–412.Google Scholar